{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:59:35Z","timestamp":1793325575387,"version":"4.5.0"},"reference-count":140,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Stress and Chaperones"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.cstres.2024.05.005","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T15:36:11Z","timestamp":1718292971000},"page":"519-539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":127,"title":["An update on the status of HSP90 inhibitors in cancer clinical trials"],"prefix":"10.1016","volume":"29","author":[{"given":"Shraddha","family":"Rastogi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahoko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunmin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane B.","family":"Trepel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Len","family":"Neckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.cstres.2024.05.005_bib1","doi-asserted-by":"crossref","first-page":"10317","DOI":"10.3390\/ijms221910317","article-title":"Role of HSP90 in cancer","volume":"22","author":"Birbo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cstres.2024.05.005_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.860320","article-title":"Heat shock proteins and HSF1 in cancer","volume":"12","author":"Cyran","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.cstres.2024.05.005_bib3","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1158\/1541-7786.MCR-15-0234","article-title":"Maximizing the therapeutic potential of HSP90 inhibitors","volume":"13","author":"Butler","year":"2015","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.cstres.2024.05.005_bib4","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.bbamcr.2011.07.018","article-title":"Post-translational modifications of Hsp90 and their contributions to chaperone regulation","volume":"1823","author":"Mollapour","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cstres.2024.05.005_bib5","doi-asserted-by":"crossref","first-page":"6976","DOI":"10.1038\/s41598-018-25404-w","article-title":"HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation","volume":"8","author":"Kijima","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.cstres.2024.05.005_bib6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev.biochem.75.103004.142738","article-title":"Structure and mechanism of the Hsp90 molecular chaperone machinery","volume":"75","author":"Pearl","year":"2006","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.cstres.2024.05.005_bib7","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrm2918","article-title":"HSP90 at the hub of protein homeostasis: emerging mechanistic insights","volume":"11","author":"Taipale","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.cstres.2024.05.005_bib8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/bip.21292","article-title":"Hsp90 and co-chaperones twist the functions of diverse client proteins","volume":"93","author":"Zuehlke","year":"2010","journal-title":"Biopolymers"},{"issue":"9","key":"10.1016\/j.cstres.2024.05.005_bib9","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.3390\/ijms19092560","article-title":"The HSP90 family: structure, regulation, function, and implications in health and disease","volume":"19","author":"Hoter","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cstres.2024.05.005_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/bs.acr.2015.08.002","article-title":"Hsp90 in cancer: transcriptional roles in the nucleus","volume":"129","author":"Calderwood","year":"2016","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.cstres.2024.05.005_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.829520","article-title":"HSP70 and HSP90 in cancer: cytosolic, endoplasmic reticulum and mitochondrial chaperones of tumorigenesis","volume":"12","author":"Albakova","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.cstres.2024.05.005_bib12","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.bbamcr.2011.10.013","article-title":"GRP94: An HSP90-like protein specialized for protein folding and quality control in the endoplasmic reticulum","volume":"1823","author":"Marzec","year":"2012","journal-title":"Biochim Biophys Acta"},{"issue":"7","key":"10.1016\/j.cstres.2024.05.005_bib13","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/biom12070880","article-title":"The mitochondrial HSP90 paralog TRAP1: structural dynamics, interactome, role in metabolic regulation, and inhibitors","volume":"12","author":"Joshi","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.cstres.2024.05.005_bib14","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.1158\/1078-0432.CCR-14-0174","article-title":"Plasma levels of heat shock protein 90 alpha associated with lung cancer development and treatment responses","volume":"20","author":"Shi","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cstres.2024.05.005_bib15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12885-019-6489-0","article-title":"Diagnostic value of plasma HSP90alpha levels for detection of hepatocellular carcinoma","volume":"20","author":"Wei","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cstres.2024.05.005_bib16","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.7946","article-title":"High expression of HSP90 is associated with poor prognosis in patients with colorectal cancer","volume":"7","author":"Zhang","year":"2019","journal-title":"PeerJ"},{"key":"10.1016\/j.cstres.2024.05.005_bib17","article-title":"Plasma HSP90AA1 predicts the risk of breast cancer onset and distant metastasis","volume":"9","author":"Liu","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.cstres.2024.05.005_bib18","first-page":"W98","article-title":"GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses","volume":"45","author":"Tang","year":"2017","journal-title":"Nucl\u00a0Acids Res"},{"issue":"16","key":"10.1016\/j.cstres.2024.05.005_bib19","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.3390\/cells11162479","article-title":"Hsp90: from cellular to organismal proteostasis","volume":"11","author":"Somogyvari","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.cstres.2024.05.005_bib20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2174\/1568009619666191202101330","article-title":"Old and new approaches to target the Hsp90 chaperone","volume":"20","author":"Sanchez","year":"2020","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.cstres.2024.05.005_bib21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-1-61779-295-3_3","article-title":"Hsp90 and client protein maturation","volume":"787","author":"Wayne","year":"2011","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.cstres.2024.05.005_bib22","unstructured":"Didier Picard. HSP90 interactors. Secondary HSP90 Interactors; 2023.\u00a0https:\/\/www.picard.ch\/downloads\/Hsp90interactors.pdf."},{"key":"10.1016\/j.cstres.2024.05.005_bib23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2174\/138161213804143725","article-title":"The therapeutic target Hsp90 and cancer hallmarks","volume":"19","author":"Miyata","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.cstres.2024.05.005_bib24","article-title":"Linking hsp90's role as an evolutionary capacitator to the development of cancer","volume":"28","author":"Lacey","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.cstres.2024.05.005_bib25","first-page":"275","article-title":"HSP90: enabler of cancer adaptation","volume":"3","author":"Jaeger","year":"2019","journal-title":"Ann\u00a0Rev\u00a0Cancer Biol"},{"issue":"1","key":"10.1016\/j.cstres.2024.05.005_bib26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3892\/or.2022.8443","article-title":"HSP90 inhibitors and cancer: prospects for use in targeted therapies (Review)","volume":"49","author":"Li","year":"2023","journal-title":"Oncol Rep"},{"key":"10.1016\/j.cstres.2024.05.005_bib27","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.apsb.2020.11.015","article-title":"The disruption of protein-protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibition","volume":"11","author":"Serwetnyk","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.cstres.2024.05.005_bib28","doi-asserted-by":"crossref","first-page":"9459","DOI":"10.1002\/chem.202000615","article-title":"Chemical perturbation of oncogenic protein folding: from the prediction of locally unstable structures to the design of disruptors of Hsp90-client interactions","volume":"26","author":"Paladino","year":"2020","journal-title":"Chemistry"},{"key":"10.1016\/j.cstres.2024.05.005_bib29","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.chembiol.2020.01.008","article-title":"Management of Hsp90-dependent protein folding by small molecules targeting the Aha1 Co-chaperone","volume":"27","author":"Singh","year":"2020","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.cstres.2024.05.005_bib30","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.2174\/092986708786242895","article-title":"Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket","volume":"15","author":"Donnelly","year":"2008","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.cstres.2024.05.005_bib31","doi-asserted-by":"crossref","first-page":"37181","DOI":"10.1074\/jbc.M003701200","article-title":"The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone","volume":"275","author":"Marcu","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cstres.2024.05.005_bib32","doi-asserted-by":"crossref","first-page":"442","DOI":"10.7164\/antibiotics.23.442","article-title":"Geldanamycin, a new antibiotic","volume":"23","author":"DeBoer","year":"1970","journal-title":"J Antibiot"},{"key":"10.1016\/j.cstres.2024.05.005_bib33","doi-asserted-by":"crossref","first-page":"8324","DOI":"10.1073\/pnas.91.18.8324","article-title":"Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation","volume":"91","author":"Whitesell","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cstres.2024.05.005_bib34","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2174\/156802610792232088","article-title":"Macrocyclic inhibitors of hsp90","volume":"10","author":"Johnson","year":"2010","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.cstres.2024.05.005_bib35","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1517\/13543776.2011.594041","article-title":"Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010","volume":"21","author":"Messaoudi","year":"2011","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.cstres.2024.05.005_bib36","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/annonc\/mdg316","article-title":"The Hsp90 chaperone complex as a novel target for cancer therapy","volume":"14","author":"Goetz","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cstres.2024.05.005_bib37","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2174\/156802609789895728","article-title":"Update on Hsp90 inhibitors in clinical trial","volume":"9","author":"Kim","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.cstres.2024.05.005_bib38","doi-asserted-by":"crossref","first-page":"6087","DOI":"10.1158\/1078-0432.CCR-06-1015","article-title":"A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer","volume":"12","author":"Nowakowski","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cstres.2024.05.005_bib39","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1200\/JCO.2005.00.612","article-title":"Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies","volume":"23","author":"Banerji","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cstres.2024.05.005_bib40","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1200\/JCO.2005.09.119","article-title":"Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer","volume":"23","author":"Goetz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cstres.2024.05.005_bib41","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1158\/1078-0432.CCR-04-2322","article-title":"Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers","volume":"11","author":"Ramanathan","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cstres.2024.05.005_bib42","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1158\/1078-0432.CCR-06-1863","article-title":"Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer","volume":"13","author":"Solit","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cstres.2024.05.005_bib43","unstructured":"Clinicaltrials.gov\/17AAG. 17AAG. In Secondary 17AAG. https:\/\/www.clinicaltrials.gov\/ct2\/results?cond=&term=TANESPIMYCIN%09&cntry=&state=&city=&dist\u3009= https:\/\/classic.clinicaltrials.gov\/."},{"key":"10.1016\/j.cstres.2024.05.005_bib44","unstructured":"Beacon\u00a0TM.\u00a0Bristol-Myers Squibb halts development of tanespimycin. In\u00a0Secondary Bristol-Myers Squibb Halts Development of Tanespimycin;\u00a02010.\u00a0https:\/\/myelomabeacon.org\/news\/2010\/07\/22\/tanespimycin-development-halted\/."},{"key":"10.1016\/j.cstres.2024.05.005_bib45","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1517\/13543784.2014.902442","article-title":"Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions","volume":"23","author":"Jhaveri","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.cstres.2024.05.005_bib46","unstructured":"Clinicaltrials.gov\/17-DMAG. 17 DMAG. In\u00a0Secondary 17 DMAG.\u00a0https:\/\/www.clinicaltrials.gov\/search?intr=17-DMAG."},{"key":"10.1016\/j.cstres.2024.05.005_bib47","first-page":"1961","article-title":"A Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of intravenous alvespimycin (KOS-1022) in patients with refractory hematological malignancies [abstract].","volume":"108","author":"Lancet","year":"2006","journal-title":"ASH Annu. Meet. Abstr"},{"key":"10.1016\/j.cstres.2024.05.005_bib48","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.bbamcr.2011.10.008","article-title":"Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers","volume":"1823","author":"Jhaveri","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cstres.2024.05.005_bib49","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.drudis.2007.10.007","article-title":"Development and application of Hsp90 inhibitors","volume":"13","author":"Solit","year":"2008","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.cstres.2024.05.005_bib50","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00280-013-2134-9","article-title":"Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors","volume":"71","author":"Saif","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cstres.2024.05.005_bib51","unstructured":"Biogen. A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Pharmacodynamic Study of Intravenously Administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in Patients with ZAP-70 Positive B-Cell Chronic Lymphocytic Leukemia (CLL); 2008. https:\/\/www.biogentriallink.com\/content\/dam\/global-development\/general\/biogen-trial-link\/educational\/en-us\/pdf\/csr\/NCT00319930-Synopsis.pdf."},{"key":"10.1016\/j.cstres.2024.05.005_bib52","unstructured":"NCT00820768 Cg\u00a0-. A trial of ABI-010 & ABI-007 in patients with advanced non-hematologic malignancies. In\u00a0Secondary A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies.\u00a0https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00820768."},{"key":"10.1016\/j.cstres.2024.05.005_bib53","unstructured":"Infinity\u00a0Pharmaceuticals I. Secondary Infinity Presents Data on Retaspimycin Hydrochloride, a Novel Hsp90 Inhibitor, in Non-Small Cell Lung Cancer at ASCO Meeting; 2011.\u00a0https:\/\/www.sec.gov\/Archives\/edgar\/data\/1113148\/000119312511159939\/dex993.htm."},{"key":"10.1016\/j.cstres.2024.05.005_bib54","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10549-013-2510-5","article-title":"A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer","volume":"139","author":"Modi","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cstres.2024.05.005_bib55","unstructured":"Biotech\u00a0F. Infinity halts RING trial in advanced gastrointestinal stromal tumors. In\u00a0Secondary Infinity Halts RING Trial in Advanced Gastrointestinal Stromal Tumors;\u00a02009.\u00a0https:\/\/www.fiercebiotech.com\/biotech\/infinity-halts-ring-trial-advanced-gastrointestinal-stromal-tumors."},{"key":"10.1016\/j.cstres.2024.05.005_bib56","doi-asserted-by":"crossref","first-page":"B101","DOI":"10.1158\/1535-7163.TARG-11-B101","article-title":"Safety, tolerability, and pharmacokinetics of IPI-493, an oral Hsp90 inhibitor, in patients with advanced cancers","volume":"10","author":"Neil","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cstres.2024.05.005_bib57","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/171344a0","article-title":"A new antifungal substance of fungal origin","volume":"171","author":"Delmotte","year":"1953","journal-title":"Nature"},{"key":"10.1016\/j.cstres.2024.05.005_bib58","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1379\/1466-1268(1998)003<0100:ARBTTN>2.3.CO;2","article-title":"Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin","volume":"3","author":"Schulte","year":"1998","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.cstres.2024.05.005_bib59","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/med.21351","article-title":"Natural product inspired N-terminal Hsp90 inhibitors: from bench to bedside?","volume":"36","author":"Khandelwal","year":"2016","journal-title":"Med Res Rev"},{"key":"10.1016\/j.cstres.2024.05.005_bib60","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2174\/138955709787316056","article-title":"Natural product inhibitors of Hsp90: potential leads for drug discovery","volume":"9","author":"Amolins","year":"2009","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.cstres.2024.05.005_bib61","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1074-5521(01)00015-1","article-title":"A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells","volume":"8","author":"Chiosis","year":"2001","journal-title":"Chem Biol"},{"key":"10.1016\/j.cstres.2024.05.005_bib62","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.2174\/156802609789895737","article-title":"Purine-scaffold Hsp90 inhibitors","volume":"9","author":"Taldone","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.cstres.2024.05.005_bib63","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2015.06.007","article-title":"PU-H71: An improvement on nature's solutions to oncogenic Hsp90 addiction","volume":"99","author":"Trendowski","year":"2015","journal-title":"Pharmacol Res"},{"issue":"9","key":"10.1016\/j.cstres.2024.05.005_bib64","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.3390\/cancers12092712","article-title":"The unique pharmacometrics of small molecule therapeutic drug tracer imaging for clinical oncology","volume":"12","author":"Dunphy","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.cstres.2024.05.005_bib65","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/2147763","article-title":"Heat shock protein 90 (HSP90) inhibitors as anticancer medicines: a review on the computer-aided drug discovery approaches over the past five years","volume":"2022","author":"Magwenyane","year":"2022","journal-title":"Comput Math Methods Med"},{"key":"10.1016\/j.cstres.2024.05.005_bib66","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3892\/ol.2014.2121","article-title":"A novel cyclic pentapeptide, H-10, inhibits B16 cancer cell growth and induces cell apoptosis","volume":"8","author":"Zhang","year":"2014","journal-title":"Oncol Lett"},{"key":"10.1016\/j.cstres.2024.05.005_bib67","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.3892\/ol.2015.4025","article-title":"Novel cyclic pentapeptide H-15 induces differentiation and inhibits proliferation in murine melanoma B16 cells","volume":"11","author":"Liu","year":"2016","journal-title":"Oncol Lett"},{"key":"10.1016\/j.cstres.2024.05.005_bib68","first-page":"5887","article-title":"A LY-15, a novel cyclic pentapeptide that inhibits B16 cell proliferation and migration and induces cell apoptosis","volume":"15","author":"Wang","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.cstres.2024.05.005_bib69","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s10495-019-01577-1","article-title":"Inhibitors of HSP90 in melanoma","volume":"25","author":"Mielczarek-Lewandowska","year":"2020","journal-title":"Apoptosis"},{"key":"10.1016\/j.cstres.2024.05.005_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102700","article-title":"Diptoindonesin G is a middle domain HSP90 modulator for cancer treatment","volume":"298","author":"Donahue","year":"2022","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cstres.2024.05.005_bib71","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/j.bbagen.2017.05.006","article-title":"Targeting the Hsp90C-terminal domain to induce allosteric inhibition and selective client downregulation","volume":"1861","author":"Goode","year":"2017","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"10.1016\/j.cstres.2024.05.005_bib72","unstructured":"clinicaltrials.gov. HSP90. In\u00a0Secondary HSP90. https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=HSP90&cntry=&state=&city=&dist\u3009= https:\/\/classic.clinicaltrials.gov\/."},{"key":"10.1016\/j.cstres.2024.05.005_bib73","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1158\/1535-7163.MCT-14-0452","article-title":"Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models","volume":"13","author":"Smyth","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cstres.2024.05.005_bib74","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1349-7006.2011.02191.x","article-title":"The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer","volume":"103","author":"Graham","year":"2012","journal-title":"Cancer Sci"},{"issue":"6","key":"10.1016\/j.cstres.2024.05.005_bib75","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.3390\/cells11061046","article-title":"The heat shock protein 90 inhibitor, AT13387, protects the alveolo-capillary barrier and prevents HCl-induced chronic lung injury and pulmonary fibrosis","volume":"11","author":"Colunga Biancatelli","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.cstres.2024.05.005_bib76","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1158\/1078-0432.CCR-14-0979","article-title":"First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors","volume":"21","author":"Shapiro","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cstres.2024.05.005_bib77","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1038\/s41598-020-62293-4","article-title":"The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approach","volume":"10","author":"Spiegelberg","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.cstres.2024.05.005_bib78","unstructured":"Clinicaltrials.gov\/AT13387. AT13387. In Secondary AT13387. https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=AT13387&cntry=&state=&city=&dist."},{"key":"10.1016\/j.cstres.2024.05.005_bib79","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1158\/1078-0432.CCR-18-3212","article-title":"Pharmacodynamic and clinical results from a phase I\/II study of the HSP90 inhibitor onalespib in combination with abiraterone acetate in prostate cancer","volume":"25","author":"Slovin","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cstres.2024.05.005_bib80","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00280-020-04176-z","article-title":"Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors","volume":"86","author":"Do","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cstres.2024.05.005_bib81","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.cllc.2021.05.001","article-title":"Erlotinib and onalespib lactate focused on EGFR exon 20 insertion non-small cell lung cancer (NSCLC): a California Cancer Consortium Phase I\/II Trial (NCI 9878)","volume":"22","author":"Riess","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cstres.2024.05.005_bib82","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/s41416-021-01664-8","article-title":"Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours","volume":"126","author":"Konstantinopoulos","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cstres.2024.05.005_bib83","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.34730","article-title":"Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors","volume":"129","author":"Mooradian","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.cstres.2024.05.005_bib84","doi-asserted-by":"crossref","DOI":"10.1186\/bcr1996","article-title":"NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models","volume":"10","author":"Jensen","year":"2008","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.cstres.2024.05.005_bib85","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/SLA.0000000000001467","article-title":"Preclinical Study of AUY922, a Novel Hsp90 Inhibitor, in the Treatment of Esophageal Adenocarcinoma","volume":"264","author":"Kosovec","year":"2016","journal-title":"Ann Surg"},{"key":"10.1016\/j.cstres.2024.05.005_bib86","unstructured":"Pharmabiz.com. Vernalis extends cancer research tie-up with Novartis.\u00a0In\u00a0Secondary Vernalis Extends Cancer Research Tie-up with Novartis;\u00a02004.\u00a0http:\/\/test.pharmabiz.com\/news\/vernalis-extends-cancer-research-tie-up-with-novartis-23200."},{"key":"10.1016\/j.cstres.2024.05.005_bib87","unstructured":"clinicaltrials.gov\/AUY922. AUY922.https:\/\/classic.clinicaltrials.gov\/."},{"key":"10.1016\/j.cstres.2024.05.005_bib88","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1158\/1078-0432.CCR-12-3404","article-title":"First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors","volume":"19","author":"Sessa","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cstres.2024.05.005_bib89","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jtho.2017.11.131","article-title":"Phase 2 study of the HSP-90 inhibitor AUY922 in previously treated and molecularly defined patients with advanced non-small cell lung cancer","volume":"13","author":"Felip","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cstres.2024.05.005_bib90","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/annonc\/mdy336","article-title":"Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions","volume":"29","author":"Piotrowska","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cstres.2024.05.005_bib91","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1158\/1535-7163.MCT-21-0334","article-title":"HSP90-specific nIR probe identifies aggressive prostate cancers: translation from preclinical models to a human phase I study","volume":"21","author":"Osada","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cstres.2024.05.005_bib92","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s42003-020-0956-7","article-title":"Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumors","volume":"3","author":"Kaneko","year":"2020","journal-title":"Commun Biol"},{"key":"10.1016\/j.cstres.2024.05.005_bib93","unstructured":"Clinicaltrials.gov\/HS-201. HS201. Secondary HS201.\u00a0https:\/\/www.clinicaltrials.gov\/search?intr=HS201."},{"key":"10.1016\/j.cstres.2024.05.005_bib94","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/15384047.2022.2029132","article-title":"Feasibility and safety of targeting mitochondria for cancer therapy - preclinical characterization of gamitrinib, a first-in-class, mitochondriaL-targeted small molecule Hsp90 inhibitor","volume":"23","author":"Hayat","year":"2022","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"10.1016\/j.cstres.2024.05.005_bib95","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3390\/biom12060786","article-title":"TRAP1 chaperones the metabolic switch in cancer","volume":"12","author":"Wengert","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.cstres.2024.05.005_bib96","unstructured":"Foxchase\/news\/gamitrinib. Fox Chase Cancer Center, The Wistar Institute announce opening of phase 1 clinical trial of anticancer drug candidate. In\u00a0Secondary Fox Chase Cancer Center, The Wistar Institute Announce Opening of Phase 1 Clinical Trial of Anticancer Drug Candidate; 2021.\u00a0https:\/\/www.foxchase.org\/news\/2021\u201312-02-fox-chase-cancer-center-the-wistar-institute-announce-opening-of-phase-1-clinical-trial-of-anticancer-drug-candidate."},{"key":"10.1016\/j.cstres.2024.05.005_bib97","unstructured":"clinicaltrials.gov\/Gamitrinib. A phase I safety and pharmacokinetic study of Gamitrinib administered intravenously to patients with advanced cancer. In Secondary A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer.\u00a0https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04827810?term=gamitrinib&draw=2&rank=1."},{"key":"10.1016\/j.cstres.2024.05.005_bib98","unstructured":"MSKCC.org\/news. Bull\u2019s-eye: Imaging technology could confirm when a drug is going to the right place. In\u00a0Secondary Bull\u2019s-Eye: Imaging Technology Could Confirm When a Drug Is Going to the Right Place;\u00a02019.\u00a0https:\/\/www.mskcc.org\/news\/bull-s-eye-imaging-technology-could-confirm-when-drug-going-right-place."},{"key":"10.1016\/j.cstres.2024.05.005_bib99","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s10637-017-0495-3","article-title":"First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile","volume":"36","author":"Speranza","year":"2018","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.cstres.2024.05.005_bib100","unstructured":"PU-H71\/NCT01581541. PU-H71 in patients with solid tumors and low-grade non-Hodgkin's lymphoma that have not responded to standard treatment. In Secondary PU-H71 in Patients With Solid Tumors and Low-grade Non-Hodgkin's Lymphoma that Have not Responded to Standard Treatment; 2017.\u00a0https:\/\/www.clinicaltrials.gov\/study\/NCT01581541?term=NCT01581541&rank=1."},{"key":"10.1016\/j.cstres.2024.05.005_bib101","doi-asserted-by":"crossref","first-page":"5178","DOI":"10.1158\/1078-0432.CCR-19-3704","article-title":"First-in-human trial of epichaperome-targeted PET in patients with cancer","volume":"26","author":"Dunphy","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cstres.2024.05.005_bib102","article-title":"Measuring tumor epichaperome expression using [(124)I] PU-H71 positron emission tomography as a biomarker of response for PU-H71 plus Nab-Paclitaxel in HER2-negative metastatic breast cancer","volume":"4","author":"Jhaveri","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.cstres.2024.05.005_bib103","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13045-021-01039-9","article-title":"Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL","volume":"14","author":"Chen","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.cstres.2024.05.005_bib104","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1016\/j.ejca.2014.07.017","article-title":"Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours","volume":"50","author":"Infante","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cstres.2024.05.005_bib105","unstructured":"NCI-Drug\u00a0Dictionary. SNX-5422-mesylate. Secondary SNX-5422-mesylate.\u00a0https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-drug\/def\/hsp90-inhibitor-snx-5422-mesylate."},{"key":"10.1016\/j.cstres.2024.05.005_bib106","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2021.10.001","article-title":"Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers","volume":"162","author":"Gutierrez","year":"2021","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.cstres.2024.05.005_bib107","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24055014","article-title":"Role of ganetespib, an HSP90 inhibitor, in cancer therapy: from molecular mechanisms to clinical practice","volume":"24","author":"Youssef","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cstres.2024.05.005_bib108","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1158\/1078-0432.CCR-11-2967","article-title":"Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer","volume":"18","author":"Shimamura","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cstres.2024.05.005_bib109","first-page":"1466","article-title":"STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer","volume":"11","author":"Wang","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.cstres.2024.05.005_bib110","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.2147\/OTT.S245813","article-title":"HSP90 inhibitor ganetespib (STA-9090) inhibits tumor growth in c-Myc-dependent esophageal squamous cell carcinoma","volume":"13","author":"Guan","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.cstres.2024.05.005_bib111","unstructured":"Clinicaltrials.gov\/STA9090. STA9090. Secondary STA9090.\u00a0https:\/\/www.clinicaltrials.gov\/search?intr=STA9090."},{"key":"10.1016\/j.cstres.2024.05.005_bib112","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13058-017-0879-5","article-title":"A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer","volume":"19","author":"Jhaveri","year":"2017","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.cstres.2024.05.005_bib113","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1634\/theoncologist.2018-0203","article-title":"A phase I study of ganetespib and Ziv-Aflibercept in patients with advanced carcinomas and sarcomas","volume":"23","author":"Meehan","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.cstres.2024.05.005_bib114","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/CMR.0000000000000509","article-title":"Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma","volume":"28","author":"Shah","year":"2018","journal-title":"Melanoma Res"},{"key":"10.1016\/j.cstres.2024.05.005_bib115","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1158\/1078-0432.CCR-12-3381","article-title":"A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer","volume":"19","author":"Socinski","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cstres.2024.05.005_bib116","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1093\/annonc\/mdv220","article-title":"A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)","volume":"26","author":"Ramalingam","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cstres.2024.05.005_bib117","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/JCO.19.00816","article-title":"Randomized phase III study of ganetespib, a heat shock protein 90 inhibitor, with docetaxel versus docetaxel in advanced non-small-cell lung cancer (GALAXY-2)","volume":"38","author":"Pillai","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cstres.2024.05.005_bib118","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1158\/1078-0432.CCR-20-1306","article-title":"Ganetespib in combination with pemetrexed-platinum chemotherapy in patients with pleural mesothelioma (MESO-02): a phase Ib trial","volume":"26","author":"Fennell","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cstres.2024.05.005_bib119","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.7150\/jca.17816","article-title":"In vitro cytotoxic activities of the oral platinum(IV) prodrug oxoplatin and HSP90 inhibitor ganetespib against a panel of gastric cancer cell lines","volume":"8","author":"Klameth","year":"2017","journal-title":"J Cancer"},{"key":"10.1016\/j.cstres.2024.05.005_bib120","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s10637-019-00889-y","article-title":"A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer","volume":"38","author":"Goyal","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.cstres.2024.05.005_bib121","unstructured":"ExelixisInc.news\/XL888. Exelixis Files IND Application for\u00a0XL888. In Secondary Exelixis Files IND Application for XL888; 2008.\u00a0https:\/\/ir.exelixis.com\/news-releases\/news-release-details\/exelixis-files-ind-application-xl888."},{"key":"10.1016\/j.cstres.2024.05.005_bib122","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1158\/1078-0432.CCR-18-0565","article-title":"Combined BRAF and HSP90 inhibition in patients with unresectable BRAF (V600E)-mutant melanoma","volume":"24","author":"Eroglu","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cstres.2024.05.005_bib123","first-page":"830","article-title":"Phase Ib trial of pembrolizumab and XL888 in patients with advanced gastrointestinal malignancies: results of the dose-escalation phase","volume":"38","author":"Akce","year":"2020","journal-title":"J\u00a0Clin\u00a0Oncol"},{"key":"10.1016\/j.cstres.2024.05.005_bib124","unstructured":"Pharma T. Taiho pharmaceutical's TAS-116, an oral HSP90 inhibitor, shows significantly prolonged progression-free survival in patients with GIST in phase-III clinical trial;\u00a02021. https:\/\/www.taiho.co.jp\/en\/release\/2021\/20210222.html."},{"key":"10.1016\/j.cstres.2024.05.005_bib125","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1158\/1535-7163.MCT-14-0219","article-title":"TAS-116, a highly selective inhibitor of heat shock protein 90alpha and beta, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models","volume":"14","author":"Ohkubo","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cstres.2024.05.005_bib126","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/s41416-019-0688-y","article-title":"TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naive and imatinib-resistant gastrointestinal stromal tumours","volume":"122","author":"Saito","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cstres.2024.05.005_bib127","unstructured":"Clinicaltrial.gov. TAS-116. Secondary TAS-116. https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=TAS-116&cntry=&state=&city=&dist=."},{"key":"10.1016\/j.cstres.2024.05.005_bib128","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1158\/1535-7163.MCT-18-0831","article-title":"First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in patients with advanced solid tumors","volume":"18","author":"Shimomura","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cstres.2024.05.005_bib129","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejca.2019.08.009","article-title":"Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial","volume":"121","author":"Doi","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cstres.2024.05.005_bib130","doi-asserted-by":"crossref","first-page":"e008210","DOI":"10.1136\/jitc-2023-008210","article-title":"Multiomic molecular characterization of the response to combination immunotherapy in MSS\/pMMR metastatic colorectal cancer.","volume":"12","author":"Takei","year":"2024","journal-title":"J Immuno Ther Cancer"},{"key":"10.1016\/j.cstres.2024.05.005_bib131","doi-asserted-by":"crossref","first-page":"6709","DOI":"10.1158\/1078-0432.CCR-21-1929","article-title":"TAS-116 (Pimitespib), an oral HSP90 inhibitor, in combination with nivolumab in patients with colorectal cancer and other solid tumors: an open-label, dose-finding, and expansion phase Ib trial (EPOC1704)","volume":"27","author":"Kawazoe","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cstres.2024.05.005_bib132","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.annonc.2022.05.518","article-title":"Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial","volume":"33","author":"Kurokawa","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cstres.2024.05.005_bib133","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s40265-022-01764-6","article-title":"Pimitespib: first Approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.cstres.2024.05.005_bib134","first-page":"v172","article-title":"First in human phase I\/IIa study of PEN-866, a heat shock protein 90 (HSP90) ligand\u2013SN38 conjugate for patients with advanced solid tumours: phase I results","volume":"30","author":"Bendell","year":"2019","journal-title":"Ann\u00a0Oncol"},{"key":"10.1016\/j.cstres.2024.05.005_bib135","unstructured":"NCI-Drug\u00a0Dictionary. HSP90-targeted SN-38 conjugate PEN-866. Secondary HSP90-targeted SN-38 conjugate PEN-866.\u00a0https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-drug\/def\/locnartecan?redirect=true."},{"key":"10.1016\/j.cstres.2024.05.005_bib136","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejca.2022.06.045","article-title":"Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trials","volume":"173","author":"Salawu","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cstres.2024.05.005_bib137","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/412985","article-title":"Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls","volume":"2010","author":"Bohonowych","year":"2010","journal-title":"J Oncol"},{"key":"10.1016\/j.cstres.2024.05.005_bib138","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nrd1497","article-title":"Pharmacogenomics: bench to bedside","volume":"3","author":"Weinshilboum","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cstres.2024.05.005_bib139","doi-asserted-by":"crossref","first-page":"11878","DOI":"10.1073\/pnas.1105160108","article-title":"Targeting the regulation of androgen receptor signaling by the heat shock protein 90cochaperone FKBP52 in prostate cancer cells","volume":"108","author":"De Leon","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cstres.2024.05.005_bib140","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.chembiol.2023.06.026","article-title":"Catalytic inhibitor of Protein Phosphatase 5 activates the extrinsic apoptotic pathway by disrupting complex II in kidney cancer","volume":"30","author":"Ahanin","year":"2023","journal-title":"Cell Chem Biol"}],"container-title":["Cell Stress and Chaperones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1355814524000774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1355814524000774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T18:11:21Z","timestamp":1723831881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1355814524000774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":140,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1355814524000774"],"URL":"https:\/\/doi.org\/10.1016\/j.cstres.2024.05.005","relation":{},"ISSN":["1355-8145"],"issn-type":[{"value":"1355-8145","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An update on the status of HSP90 inhibitors in cancer clinical trials","name":"articletitle","label":"Article Title"},{"value":"Cell Stress and Chaperones","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cstres.2024.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}